A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy.

Trial Profile

A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2013

At a glance

  • Drugs MVA BN HER2 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 May 2013 Additional lead centre (Bavarian Nordic) added as reported by ClinicalTrials.gov.
    • 24 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top